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Abstract
Background: IL-17-secreting CD8+ T cells (Tc17 subset) have recently been defined as a subpopulation of effector T cells
implicated in the pathogenesis of autoimmune diseases. The role of Tc17 and correlation with Th17 cells in the
pathophysiology of immune thrombocytopenia (ITP) remain unsettled.
Design and Methods: We studied 47 ITP patients (20 newly-diagnosed and 27 with complete response) and 34 healthy
controls. IL-17-producing CD3+CD8+ cells (Tc17) and IL-17-producing CD3+CD82 cells (Th17) were evaluated by flow
cytometry and expressed as a percentage of the total number of CD3+ cells. Specific anti-platelet glycoprotein (GP) GPIIb/
IIIa and/or GPIb/IX autoantibodies were measured by modified monoclonal antibody specific immobilization of platelet
antigens. Peripheral blood mononuclear cells of ITP patients were isolated, incubated in the presence of 0, 0.25, 0.5, or
1 mmol/L of dexamethasone for 72 h, and collected to detect Tc17 and Th17 cells by flow cytometric analysis.
Results: IL-17 was expressed on CD3+CD82 and CD3+CD8+ T cells. The percentages of Tc17 and Th17 cells in newly-
diagnosed patients were significantly elevated compared to controls, and Tc17 was decreased after clinical treatment. The
Th17:Tc17 ratio was significantly lower in newly-diagnosed patients compared with controls, and was increased in patients
who had complete response. There was a significantly positive correlation between Tc17 and Th17 cells in the control
group, but not in the ITP patients. A positive correlation existed between Tc17 and the CD8:CD4 ratio, as well as CD8+ cells
in patients with ITP. The frequencies of Tc17 were marginally higher in autoantibody-negative patients than autoantibody-
positive patients. Moreover, both Tc17 and Th17 cell percentages decreased as the concentration of dexamethasone in the
culture media increased in ITP patients.
Conclusions: Tc17 and the Th17 subset are involved in the immunopathology of ITP. Blocking the abnormally increased
number of Tc17 may be a reasonable therapeutic strategy for ITP.
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Introduction
Immune thrombocytopenia (ITP) is characterized by a low
platelet count, which is the result of increased platelet destruction
and insufficient platelet production [1]. The pathophysiology of
ITP is heterogeneous and complex. T-lymphocyte abnormalities
are considered important in patients with ITP. Many cellular
mechanisms of immune modulation have been described in
patients with ITP, such as T helper 1 (Th1) bias [2], a decreased
number or defective suppressive function of regulatory T cells [3],
and platelet destruction by cytotoxic T lymphocytes (CTLs) [4].
More recently, utilizing a new animal model of ITP it has been
shown that CTLs mediate thrombocytopenia [5]. However, the
mechanism of cellular immune abnormalities in patients with ITP
remains unclear.
Th17 cells comprise a novel Th cell subset characterized by the
production of IL-17 [6]. Th17 cells have been shown to play a
crucial role in the induction of autoimmune diseases, including
rheumatoid arthritis, experimental autoimmune encephalomyelitis
(EAE), and allergen-specific responses [7]. In our previous work,
we determined the number of Th17 cells in the peripheral blood of
ITP patients and healthy controls by flow cytometry through
intracellular cytokine analysis, and demonstrated for the first time
that Th17 cells are elevated in ITP patients [8]–[][10]. More
recently, a completely new subset of IL-17-secreting CD8+ effector
cells, so-called Tc17, have been described with a quite different
phenotype from other cytolytic T cells. Similar to Th17 cells, naı ¨ve
CD8+ T cells differentiate into Tc17 cells in the presence of IL-6
and IL-21 along with TGF-b [7]. Tc17 cells secrete IL-17A and
IL-17F, and little or no IFN-r and IL-4. In contrast to Tc1 or Tc2,
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cytolytic activity against antigen (Ag)-loaded targets [11].
Tc17 have been shown to be involved in various conditions.
Tc17 can protect mice against lethal influenza challenge, while
Tc17 protection is accompanied by greater neutrophil influx into
the lung than in Tc1-injected mice [11]. Tc17 have also been
shown to play an important role in controlling the growth of B16
malignant melanoma in mice via the recruitment of neutrophils
[12]. Moreover, Tc17 promote acute graft-versus-host disease
(aGVHD) in bone marrow transplantation, and the occurrence of
aGVHD is reduced through decreased IL-17 secretion by T cells
[13]. Tc17 are also implicated in the pathogenesis of some human
autoimmune diseases, such as psoriasis [14] and systemic lupus
erythematosus (SLE) [15]. However, the characteristics of Tc17
and the correlation between Tc17 and Th17 in ITP patients have
not been systematically investigated.
To further investigate the possible role of Tc17 and Th17 cells
in the pathogenesis of ITP, we measured the number of Tc17 and
correlated the number to Th17 cells and evaluated the clinical
relevance.
Methods
Ethics Statement
Our research was approved by the Medical Ethical Committee
of Qilu Hospital of Shandong University. An informed consent
document was obtained from each participant. The informed
consent stated that the unused portion or excess of the peripheral
blood drawn from patients for complete blood cell counts was as
the source of Tc17 in ITP research, or the peripheral blood drawn
from healthy subjects for this research was voluntary.
Patients and Controls
Forty-seven ITP patients (25 females and 22 males; age range,
16–80 years; median age, 41 years), including 20 newly-diagnosed
and 27 ITP patients who had complete response (CR) after
glucocorticoid therapy, intravenous gamma globulin, and/or
splenectomy were enrolled in this study. Enrollment took place
between May 2010 and June 2011 in the Department of
Hematology of Qilu Hospital (Jinan, China). The platelet counts
ranged between 1 and 70610
9/L, with a median count of
24.57610
9/L. The megakaryocyte counts in the bone marrow
smear (1.5 cm63.0 cm) ranged between 26 and 560, with a
median count of 173. Patients with diabetes, hypertension,
cardiovascular diseases, pregnancy, active or chronic infections,
or connective tissue diseases, such as SLE, were excluded. All of
the patients met the diagnostic criteria of ITP, as previously
described [16]. Thirty-four healthy controls were included (18
females and 16 males; age range, 20–58 years; median, 32 years).
The platelet counts of healthy controls ranged from 132 to
308610
9/L, with a median count of 229610
9/L.
Flow Cytometric Analysis
Intracellular cytokines were studied by flow cytometry to
identify the cytokine-producing cells. Briefly, heparinized periph-
eral whole blood (400 ml) with an equal volume of Roswell Park
Memorial Institute (RPMI)-1640 medium was incubated for 4 h at
37uCi n5 %C O 2 in the presence of 25 ng/mL of phorbol
myristate acetate (PMA), 1 mg/mL of ionomycin, and 1.7 mg/mL
of monensin (all from Alexis Biochemicals, San Diego, CA, USA).
PMA and ionomycin are pharmacologic T cell-activating agents
that mimic signals generated by the T cell receptor (TCR)
complex and have the advantage of stimulating T cells of any Ag
specificity. Monensin was used to block intracellular transport
mechanisms, thereby leading to an accumulation of cytokines in
the cells.
After incubation, the cells were stained with PE-Cy5-conjugated
anti-CD3 and fluorescein isothiocyanate-conjugated anti-CD8
monoclonal antibodies at room temperature in the dark for
15 min to delimit CD4+ T cells because CD4 was down-
modulated when cells were activated by PMA. After surface
staining, the cells were stained with PE-conjugated anti-IL17
monoclonal antibodies after fixation and permeabilization accord-
ing to the manufacturer’s instructions. Isotype controls were given
to enable correct compensation and confirm antibody specificity.
Stained cells were analyzed by flow cytometric analysis using a
FAC Scan cytometer equipped with CellQuest software (BD
Bioscience PharMingen, San Jose, CA, USA).
Addition of dexamethasone (DEX) to peripheral blood
mononuclear cells (PBMCs) from patients with ITP
PBMCs of ITP patients were isolated from heparinized blood by
gradient centrifugation (4006g for 20 min) on Ficoll-Paque
(Pharmacia Diagnostics, Uppsala, Sweden), and washed twice.
Then, PBMCs were adjusted to 1610
6/ml in RPMI-1640 culture
medium supplemented with 10% heat-inactivated fetal bovine
serum at a density of 2610
6 cells/well in a 6-well culture plate and
incubatedin humidified airin 5%CO2 at 37uC inthe presenceof 0,
0.25, 0.5, or 1 mmol/L of DEX. After 72 h, the PBMCs were
collected to enumerate Tc17 and Th17 by flow cytometric analysis.
Anti-platelet autoantibody determination
All plasma samples were stored at 220uC prior to use. The
specific anti-platelet GPIIb/IIIa and/or GPIb/IX autoantibodies
were analyzed by modified monoclonal antibody-specific immo-
bilization of platelet antigens (MAIPA), which was carried out as
previously described in detail by Hou et al. [17].
Statistical Analysis
The results are expressed as the median (range). Comparisons
between the two groups were assessed by the Wilcoxon rank-sum
test, and Spearman’s test was used for correlation analysis. All tests
were performed by SPSS (version 16.0; SPSS, Inc., Chicago, IL,
USA). P value,0.05 was considered statistically significant.
Results
Elevated Tc17 and Th17 cells in ITP patients
We analyzed the frequencies of Tc17 and Th17 cells based on
cytokine patterns after in vitro activation by PMA/ionomycin in
short-term cultures. The expression of a typical dot plot of IL-17
gated onCD3+ T cellsinITPpatients and healthycontrols isshown
in Fig. 1. IL-17 was expressed on CD3+CD82 and CD3+CD8+ T
cells.Comparedwithhealthycontrols(median, 0.30%;range,0.04–
1.80%), the percentage of Tc17 was significantly increased in the
newly-diagnosed patients (median, 0.79%; range, 0.25–3.58%;
P,0.0001), while there was no significant change in the patients
with CR (median, 0.39%; range, 0.10–1.54%). Tc17 were
decreased significantly in patients with CR compared to newly-
diagnosed patients (P=0.0017; Fig. 2a). We also demonstrated a
statistically significant difference in Th17 between newly-diagnosed
patients (median, 2.24%; range, 0.72–8.18%) and healthy controls
(median, 1.19%; range, 0.04–4.53%; P=0.0016; Fig. 2b), which
was similar to the results we previously reported [9].
We noted a difference in the Th17:Tc17 ratio among newly-
diagnosed patients with CR and the healthy control group. As
shown in Fig. 2c, the Th17:Tc17 ratio in newly-diagnosed patients
(median, 2.5850; range, 1.4221–3.0714) was 0.76-fold lower than
Tc17 in ITP
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26522in the healthy controls (median, 3.3852; range, 1.0000–5.8571;
P,0.0001) and 0.70-fold lower than in the patients with CR
(median, 3.6771; range, 2.3896–5.5000; P,0.0001). There were
no significant differences in the Th17:Tc17 ratio in patients with
CR compared to healthy controls (P=0.2483).
Tc17 are positively correlated with Th17 cells in healthy
controls, but not in ITP patients
The relationships between Tc17 and Th17 cells in ITP patients
and the healthy control group were investigated. As shown in
Fig. 3, the frequencies of Tc17 and Th17 cells were positively
correlated in healthy controls (r=0.7239, P,0.0001), but not in
newly-diagnosed patients (r=20.3150, P=0.1762) or patients
with CR (r=0.0773, P=0.7017).
Tc17 are positively correlated with the CD8:CD4 ratio and
the percentage of CD8+ cells in ITP patients
Because the CD4:CD8 ratio is an important index by which to
evaluate immune status, as shown in Figs. 4a and b, we
determined the difference in CD4:CD8 ratios between ITP
Figure 1.Thepercentages of circulatingTc17 and Th17 cells in ITPpatients and controls. Heparinized peripheral whole bloodfrom all subjectswas
stimulated with phorbol myristate acetate, ionomycin, and monensin for 4 h, then stained with labeled antibodies as described in the Design and Methods
section. (a) Lymphocytes were gated by flow cytometry in Gate 1. (b,d,f) CD3+T subsets were gated by flow cytometry; the plots in intern box Gate 2 represent
CD3+ T cells. (c, e, g) The percentages of circulating Tc17 and Th17 cells from ITP patients and controls; the percentage o fp o s i t i v ec e l l si ss h o w ni ne a c hp a nel.
doi:10.1371/journal.pone.0026522.g001
Tc17 in ITP
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26522patients and healthy controls. The ratio of CD4:CD8 was
decreased in ITP patients (median, 1.42; range, 0.26–4.18)
compared to healthy controls (median, 1.90; range, 0.93–3.95;
P=0.029), and the percentage of CD8+ T cells was increased in
ITP patients (median, 29.34%; range, 9.78–68.97%) compared
with healthy controls (median, 22.35%; range, 12.89–32.3%;
P=0.025).
In the study we determined the correlation of Tc17 with the
CD8:CD4 ratio, as well as CD8+ cells in ITP patients. As shown
in Figs. 5a and 5b, Tc17 and CD8:CD4 ratios were positively
related (r=0.6256, P=0.001), while Tc17 and CD8+ cells were
also positively related in ITP patients (r=0.5562, P=0.006).
Marginally elevated Tc17 in autoantibody-negative ITP
patients
Circulating anti-platelet autoantibodies are frequently detected
in ITP patients. The most common targets of anti-platelet
antibodies are the GPIIb/IIIa complex and GPIb/IX. We
determined the correlation of anti-platelet GPIIb/IIIa and/or
GPIb/IX autoantibodies with Tc17 in ITP patients. The number
of Tc17 was marginally elevated in patients who had a negative
MAIPA test (median, 1.00; range, 0.18–3.58) compared to patients
with a positive MAIPA test (median, 0.50; range, 0.23–0.96;
P=0.07).
Tc17 and Th17 cells are decreased in the presence of DEX
in PBMCs of ITP patients in vitro
To determine the response of Tc17 and Th17 cells to DEX, we
measured the changes in the percentages of Tc17 and Th17 cells
from PBMCs of ITP patients in the presence of DEX in vitro.A s
shown in Fig. 6, the percentage of Tc17 and Th17 cells decreased
with the increase in the concentration of DEX in culture media.
Clinical relevance of Tc17 in ITP patients
Because insufficient platelet production by megakaryocytes is a
main cause of ITP, we analyzed the association between Tc17 and
megakaryocytes or platelet counts in ITP patients. There was no
significant correlation between Tc17 and the megakaryocyte count
(r=0.0319, P=0.867). In addition, no significant correlation
existed between the number of Tc17 and the platelet count
(r=20.1749, P=0.301).
Discussion
ITP is an autoimmune disease in which abnormalities in cellular
immunity have been clearly demonstrated [18]. Apart from a shift
in the Th1/Th2 balance, a new T cell subset (Th17 cells), the
primary CD4+ cells producing IL-17, is often regarded as the
principal instigator of autoimmune disorders. Th17 cells are
increased in patients with chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP) [19] and psoriasis [20]. The Tc17
subset is a new unique cell lineage in terms of function and
differentiation [21]. There are considerable data showing that
Th17 cells are increased in ITP patients [9]. However, only a few
studies have focused on Tc17 in autoimmune diseases. More
recently, it has been shown that the percentages of Tc17 were
increased in psoriatic skin lesions or the peripheral blood of SLE
patients, which indicates that this type of CD8+ T cell plays a
significant role in the pathogenesis of autoimmune diseases
Figure 2. Tc17 and Th17 cells, and the Th17:Tc17 ratio in ITP
patients and controls. (a) Significantly elevated percentage of Tc17
was found in newly-diagnosed ITP patients (median, 0.79%; range,
0.25–3.58%) compared to controls (median, 0.30%; range, 0.04–1.80%;
***P,0.0001) and CR patients (median, 0.39%; range, 0.10–1.54%;
**P=0.0017). (b) Statistically elevated percentage of Th17 cells was
found in newly-diagnosed ITP patients (median, 2.24%; range, 0.72–
8.18%) compared to controls (median, 1.19%; range, 0.04–4.53%;
**P=0.0016; [similar to our previous study]). (c) The Th17:Tc17 ratio
in newly-diagnosed patients (median, 2.5850; range, 1.4221–3.0714)
was 0.76-fold lower than controls (median, 3.3852; range, 1.0000–
5.8571; ***P,0.0001) and 0.70-fold lower than CR cases (median,
3.6771; range, 2.3896–5.5000; ***P,0.0001).
doi:10.1371/journal.pone.0026522.g002
Tc17 in ITP
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infiltrated in positive patch test biopsy samples of patients with
allergic contact dermatitis (ACD), indicating that Tc17 and Th17
cells are an integral part in the immunopathology of ACD,
regardless of the nature of the triggering allergen [22]. Although
Tc17 are aberrant in these autoimmune disorders, it is still not
clear whether or not Tc17 are involved in ITP.
To study the role of Tc17 in the development of ITP, Tc17
were examined in the peripheral blood of newly-diagnosed
patients, ITP patients who achieved CR, and healthy controls.
Our results demonstrated that the number of Tc17 (defined as
CD3+CD8+IL-17+) was significantly increased in newly-diag-
nosed patients, but not in patients who had CR, which indicated
the importance of Tc17 in the development of ITP. Moreover, the
Figure 3. Correlations between Tc17 and Th17 cells in ITP
patients and controls. (a, b) No significant correlation was
demonstrated in newly-diagnosed (r=20.3150, P=0.1762) or CR ITP
patients (r=0.0773, P=0.7017); (c) A positive correlation was shown
between Tc17 and Th17 cells in controls (r=0.7239, P,0.0001).
doi:10.1371/journal.pone.0026522.g003
Figure 4. CD8 cells and CD4:CD8 ratio in ITP patients and
controls. (a) Significant difference of the CD4:CD8 ratios between ITP
patients (median, 1.42; range, 0.26–4.18) and control group (median,
1.90; range, 0.93–3.95; *P=0.029). (b) Elevated percentage of CD8+ T
cells in ITP patients (median, 29.34%; range, 9.78%–68.97%) compared
with controls (median, 22.35%; range, 12.89%–32.3%; *P=0.025).
doi:10.1371/journal.pone.0026522.g004
Tc17 in ITP
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addition of DEX in vitro, strongly suggesting that Tc17 may be
involved in the pathogenesis of ITP. Also, the number of Th17
cells was increased in newly-diagnosed ITP patients compared
with healthy controls; similar results were produced in our
previous research [9]. In the current study we confirmed the
increased number of Th17 cells in ITP patients. Moreover, due to
the similar trends in increased numbers of Th17 cells and Tc17 in
ITP patients, we compared the ratio of Th17:Tc17 between
newly-diagnosed patients, ITP patients with complete response,
and healthy controls, and showed that the Th17:Tc17 ratio was
decreased in newly-diagnosed patients compared with healthy
controls and patients who had CR. This indicated that Tc17 were
increased more predominately than Th17 in patients with active
ITP. Thus, we presume that the Tc17 subset might play a more
important role in the immunopathology of ITP patients.
In addition, the Tc17 differentiate along a developmental
program that is similar to the one described for Th17 cells
[23],[24],[25]. The positive correlation of the percentages between
Th17 cells and Tc17 in control samples suggests that Tc17 is co-
regulated with Th17 cells during differentiation in normal human
peripheral blood, and substantially advanced our understanding of
T-cell mediated immunity. Th17 cells and Tc17 may play a
cooperative or synergistic function under conditions of T cell-
mediated immunity; however, no significant correlation existed
between Tc17 and Th17 cells in the peripheral blood of ITP
patients. These results strongly support the hypothesis that there is
a pathologic differentiation of T cell subsets in patients with ITP,
which ultimately causes a derangement between Tc17 and Th17
cells.
The CD4:CD8 ratio is an important index in immune-related
diseases [26]. A low CD4:CD8 ratio may be a sign of immune
dysfunction [27]. Interestingly, in the current study we showed
that the CD4:CD8 ratio and percentage of CD8 cells were
elevated in patients with ITP compared with healthy controls.
Also, Tc17 was positively correlated with the percentage of CD8+
cells and the CD8:CD4 ratio. The results in the control group
were dissimilar. The mechanism underlying the correlation
between Tc17 and the CD4:CD8 ratio or the percentage of
CD8 cells should be clarified in future studies.
Platelet-reactive antibodies are not detected in all patients with
ITP. A subset of patients do not respond to pharmacologic
therapy, antibody-mediated platelet clearance, or B-cell suppres-
sion, suggesting the possible involvement of other pathogenic
mechanisms, such as Ag shedding, and T cell-mediated platelet
destruction or marrow suppression [4]. We detected Tc17 and
specific anti-platelet GPIIb/IIIa and/or GPIb/IX autoantibodies
in 23 patients by MAIPA. The results showed that the number of
Tc17 and titers of autoantibodies had a marginal negative
correlation, suggesting cellular and humoral immunity might be
complementary in the pathogenesis of ITP.
Taken together, our study demonstrated that the predominant
Tc17 might differentiate and develop under the influence of a
particular microenvironment and eventually cause an imbalance
in Tc17 and Th17 cell subsets in patients with ITP. The Tc17
subset could be decreased with effective clinical treatment. T-cell
function derangement has been demonstrated in patients with ITP
with abnormal T cells secreting IL-17. The elevated Tc17 may
play a potential role in the development and progression of ITP,
and blocking the abnormally increased number of Tc17 cells may
lead to a novel therapeutic strategy for ITP.
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Figure 5. Correlations of Tc17 with CD8 and CD8;CD4 in ITP.
Positive correlation of Tc17 with CD8:CD4 ratio (r=0.6256, P=0.001)
and positive correlation of Tc17 with percentage of CD8+ T cells
(r=0.5562, P=0.006) in ITP.
doi:10.1371/journal.pone.0026522.g005
Figure 6. The response of Tc17 and Th17 cells to DEX in ITP
patients. The percentages of Tc17 and Th17 cells had a decreasing
tendency with the increase in DEX concentration in culture media.
doi:10.1371/journal.pone.0026522.g006
Tc17 in ITP
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